@Davisite Did you ever end up working with Zantrene + Pembrolizumab? I was browsing through some posts from four years ago to find the answer, but even with the advanced search function, sorting through them all is hard. These days, it's obviously RC220 + Keytruda. With Keytruda coming off patent, its use will likely expand as biosimilars become accessible. Do you see anything there?
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.14 |
Change
-0.015(1.30%) |
Mkt cap ! $197.1M | |||
| Open | High | Low | Value | Volume |
| $1.16 | $1.16 | $1.13 | $170.4K | 148.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5868 | $1.14 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.14 | 2062 | 1 |
View Market Depth
| Last trade - 16.10pm 13/06/2025 (20 minute delay) ? |
| RAC (ASX) Chart |